The Dedifferentiated Liposarcoma drugs in development market research report provides comprehensive information on the therapeutics under development for Dedifferentiated Liposarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dedifferentiated Liposarcoma. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dedifferentiated Liposarcoma and features dormant and discontinued products.

GlobalData tracks 32 drugs in development for Dedifferentiated Liposarcoma by 28 companies/universities/institutes. The top development phase for Dedifferentiated Liposarcoma is phase ii with 21 drugs in that stage. The Dedifferentiated Liposarcoma pipeline has 31 drugs in development by companies and one by universities/ institutes. Some of the companies in the Dedifferentiated Liposarcoma pipeline products market are: Novartis, AstraZeneca and Chia Tai Tianqing Pharmaceutical Group.

The key targets in the Dedifferentiated Liposarcoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), and Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).

The key mechanisms of action in the Dedifferentiated Liposarcoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with six drugs in Phase II. The Dedifferentiated Liposarcoma pipeline products include 11 routes of administration with the top ROA being Intravenous and five key molecule types in the Dedifferentiated Liposarcoma pipeline products market including Small Molecule, and Monoclonal Antibody.

Dedifferentiated Liposarcoma overview

Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive type of cancer that arises from fat cells. It usually occurs in the limbs or the abdomen, and can cause pain, swelling, or a lump under the skin. DDLPS is a subtype of liposarcoma that develops from a low-grade tumor called well-differentiated liposarcoma (WDLS). The tumor undergoes a transformation to a high-grade sarcoma that is typically not lipogenic, meaning it does not produce fat. DDLPS is characterized by genetic changes involving the 12q13-15 region, which leads to the overexpression of several genes, including MDM2. DDLPS has a high risk of recurrence and metastasis, and requires surgery, radiation therapy, and chemotherapy for treatment. The prognosis of DDLPS depends on the location, size, and grade of the tumor, as well as the extent of surgical resection.

For a complete picture of Dedifferentiated Liposarcoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.